- $1.70bn
- $845.60m
- $63.52m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.31 | ||
| Price to Tang. Book | 2.31 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 26.71 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -45.08% | ||
| Return on Equity | -43.94% | ||
| Operating Margin | -654.25% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.02 | 51.84 | 60.92 | 377.71 | 63.52 | 59.77 | 63.55 | 412.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Directors
- Giuseppe Ciaramella PRE (52)
- John Evans CEO (44)
- Terry-Ann Burrell CFO (42)
- John Maraganore DRC
- Kristina Burow IND (47)
- Graham Cooper IND (51)
- Mark Fishman IND (70)
- Carole Ho IND (48)
- Kathleen Walsh IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 25th, 2017
- Public Since
- February 6th, 2020
- No. of Shareholders
- 27
- No. of Employees
- 483
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 99,784,755
- Address
- 238 Main Street, CAMBRIDGE, 02142
- Web
- https://beamtx.com/
- Phone
- +1 8573278775
- Auditors
- Deloitte & Touche LLP
Upcoming Events for BEAM
Beam Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Beam Therapeutics Inc Earnings Release
Similar to BEAM
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Beam Therapeutics share price?
As of Today at 19:32 UTC, shares in Beam Therapeutics are trading at $17.00. This share price information is delayed by 15 minutes.
How has the Beam Therapeutics share price performed this year?
Shares in Beam Therapeutics last closed at $17.00 and the price had moved by -30.07% over the past 365 days. In terms of relative price strength the Beam Therapeutics share price has underperformed the S&P500 Index by -34.25% over the past year.
What are the analyst and broker recommendations for Beam Therapeutics?
The overall consensus recommendation for Beam Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Beam Therapeutics dividend yield?
Beam Therapeutics does not currently pay a dividend.
Does Beam Therapeutics pay a dividend?
Beam Therapeutics does not currently pay a dividend.
When does Beam Therapeutics next pay dividends?
Beam Therapeutics does not currently pay a dividend.
How do I buy Beam Therapeutics shares?
To buy shares in Beam Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Beam Therapeutics?
As of the previous close price of $17.00, shares in Beam Therapeutics had a market capitalisation of $1.70bn.
Where are Beam Therapeutics shares listed?
Here are the trading details for Beam Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BEAM
What kind of share is Beam Therapeutics?
Based on an overall assessment of its quality, value and momentum Beam Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Beam Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Beam Therapeutics is $49.50. That is 191.18% above the last closing price of $17.00.
Analysts covering Beam Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$4.80 for the next financial year.
Find out moreWhat is the trend in the Beam Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beam Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -20.34%.
As of the last closing price of $17.00, shares in Beam Therapeutics were trading -32.64% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Beam Therapeutics PE Ratio?
The Beam Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $17.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Beam Therapeutics?
Beam Therapeutics' management team is headed by:
- Giuseppe Ciaramella - PRE
- John Evans - CEO
- Terry-Ann Burrell - CFO
- John Maraganore - DRC
- Kristina Burow - IND
- Graham Cooper - IND
- Mark Fishman - IND
- Carole Ho - IND
- Kathleen Walsh - IND